Recursion Pharmaceuticals Inc. $(RXRX)$ has announced the acquisition of Rallybio's full interest in their joint ENPP1 inhibitor program, REV102, designed for the treatment of hypophosphatasia $(HPP)$, a rare genetic disorder. The acquisition includes an associated backup molecule. This move grants Recursion full ownership of the program, allowing the company to expedite the development of what could become the first oral disease-modifying therapy for HPP. Currently in IND-enabling studies, REV102 is expected to enter Phase 1 clinical trials in the second half of 2026. The program aims to address the underlying cause of HPP by inhibiting the enzyme ENPP1, potentially improving bone mineralization. Results of these studies have yet to be presented.